News

DGAP-Adhoc: Heidelberg Pharma AG: Partner Magenta Therapeutics Exercises Option to Further Develop Antibody Targeted Amanitin Conjugates Targeted to CD45

DGAP-Adhoc: Heidelberg Pharma AG: Partner Magenta Therapeutics übt Option für die Weiterentwicklung von Antikörper-Amanitin-Konjugaten mit dem Zielmolekül CD45 aus

DGAP-News: Heidelberg Pharma AG: Heidelberg Pharma Announces Participation at Various Conferences

DGAP-News: Heidelberg Pharma AG: Heidelberg Pharma kündigt Teilnahme an verschiedenen Konferenzen an

DGAP-Adhoc: Eifelhöhen-Klinik AG: Tochtergesellschaft Eifelhöhen-Klinik Marmagen GmbH stellt Insolvenzantrag

Vivoryon Therapeutics to Attend and Present at Investor Conferences in November 2019

DGAP-Adhoc: Eifelhöhen-Klinik AG: Vorläufige Einstellung des Klinikbetriebes der Eifelhöhen-Klinik Marmagen GmbH

DGAP-Adhoc: CytoTools AG: Erste Eigenentwicklung einer deutschen Biotechfirma erhält Produktionsfreigabe und Marktzulassung in Indien

DGAP-News: ifa systems AG mit neuen Aufsichtsratsmitgliedern

DGAP-News: Heidelberg Pharma AG: Notice to Holders

DGAP-News: Heidelberg Pharma AG: Pflichtwandlungsmitteilung

DGAP-News: Vivoryon Therapeutics AG: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE WOULD BE UNLAWFUL.

DGAP-News: Doctolib und ifa systems AG vereinbaren Kooperation

DGAP-News: Heidelberg Pharma AG: Zwischenmitteilung für die ersten neun Monate 2019

DGAP-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2019

DGAP-News: Vivoryon Therapeutics AG: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE WOULD BE UNLAWFUL.

EQS-News: Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024

EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024

EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR

EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101

EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023

EQS-News: Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty

EQS-News: Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study

EQS-News: Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024

EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million